April 8 (Reuters) - A European Medicines Agency

committee will this week hold a meeting related to its probe

into reports of suicidal thoughts after taking diabetes and

weight loss drugs such as Novo Nordisk's Ozempic, an

agenda showed on Monday.

The agency began its review into the class of weight loss

and diabetes drugs, known as GLP-1 receptor agonists, last July

after Iceland's health regulator flagged three cases of patients

thinking about suicide or self-harm after using Novo's drugs -

diabetes drug Ozempic and weight-loss treatment Saxenda.

The list of drugs the EU regulator was looking into

includes Novo's Rybelsus, Saxenda and Victoza and Xultophy,

apart from Ozempic and Wegovy.

A preliminary review by the U.S. Food and Drug

Administration in January this year found no such link. Still,

it warned it could not definitively rule out a small risk due to

limited data.

GLP-1 receptor agonists, originally developed to help

control blood sugar in patients with diabetes, also slow

digestion and reduce hunger.